Ranbaxy Board in New Hands

Ranbaxy Board in New Hands Japan's Daiichi Sankyo has taken complete control over India's largest pharmaceutical company Ranbaxy, a company started by Bhai Mohan Singh, and transformed by his son Parvinder Singh. Last year, his grandsons Malvinder and Shivinder Singh sold their entire stake in the company to Japanese pharmaceutical giant.

The Ranbaxy board has been constituted again. Malvinder Singh who was earlier working as the MD and CEO has been removed from company board. . Atul Sobti, will shoulder the responsibility of CEO of the giant drug maker.

Apart from this, Tsutomu Une has been elected the Chairman of the Ranbaxy board.

Ranbaxy arm inks pact with AOK Baden Wutrttemberg

Ranbaxy arm inks pact with AOK Baden WutrttembergIndia's largest pharmaceutical company Ranbaxy Laboratories informed on Wednesday that its wholly-owned European subsidiary, Basics Gmbh has signed an agreement with German health insurer AOK Baden-Wutrttemberg (AOK) for

Ranbaxy voluntarily recalls nitrofurantoin capsules from US retail market

Ranbaxy voluntarily recalls nitrofurantoin capsules from US retail market

Adding to Ranbaxy Laboratories’ woes in the US, after the Food and Drugs Administration (FDA) stopped the export of the company’s drugs from two Indian facilities, is the company’s recent, voluntarily recall of all its lots of Nitrofurantoin (Monohydrate/Macrocrystals) 100 mg capsules from the US retail market, as the drugs failed to meet the US drug manufacturing standards.

Ranbaxy posts quarterly net loss of Rs 761 crore; third loss in a row!

Ranbaxy posts quarterly net loss of Rs 761 crore; third loss in a row!Exhibiting one of its worst quarterly performances ever, Ranbaxy Laboratories – now owned by Japanese firm Daiichi Sankyo - has posted its third straight quarter of losses, for the quarter ended March 31, 2009.

Citing foreign exchange instability, a 14 percent drop in its US market, and pricing strain in key markets, Ranbaxy posted a net loss of Rs 761 crore during the quarter – a dramatic turnaround from the Rs 153 crore net profit figures in 2008. In the previous two quarters, Ranbaxy posted losses of Rs 680 crore and Rs 394 crore.

UK, Australia gives clean chit to Ranbaxy’s Paonta Sahib Plant

Ranbaxy Laboratories LtdThe country's largest pharmaceutical company, Ranbaxy Laboratories Ltd has managed to get Good Manufacturing Practice (GMP) certificates from the concerned departments in the UK and Australia for its Paonta Sahib plant.

The authorities from both countries investigated the utility as per respective principles and guidelines of GMP in 2006 and finally gave nod to drug manufacturing after re-examining the plant in 2008.

USFDA approvals marketing of Ranbaxy's migraine drug

USFDA approvals marketing of Ranbaxy's migraine drugThe US Food and Drug Administration (USFDA) has approved the marketing of Ranbaxy Laboratories' migraine drug, Imitrex (Sumatriptan), a low cost version of migraine drug GlaxoSmithKine, in the US market.

A spokesman of Rabnbaxy said, "We have received the US Food and Drug Administration's (USFDA) approval for 100 mg Sumatriptan."

The regulator provides 180-day marketing exclusivity for its marketing in 100 mg dosage which was earlier rejected by it on December 2008.

Ranbaxy plans to Shift Some Generic Drug Production to US

Ranbaxy plans to Shift Some Generic Drug Production to USRanbaxy Laboratories CEO Malvinder Singh said that due to an import ban by the US authorities, his firm may shift some generic drug production from India to the US.

"We will transfer (production of) some products from India to America. Also, we are looking at making some acquisitions of manufacturing assets," said Mr Singh, at a media reception held by Japanese drugmaker Daiichi Sankyo.

Ranbaxy Get USFDA Approval For Esomeprazole Magnesium

RanbaxyIndia’s Pharmaceutical major, Ranbaxy Laboratories Ltd has received tentative approval from the U.S. Food and Drug Administration for Esomeprazole Magnesium Delayed-Release Capsules, 20 mg (base) and 40 mg (base).

Esomeprazole is indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis, to maintain symptom resolution and healing of erosive esophagitis and for treatment of heartburn and other symptoms associated with Gastroesophageal Reflux Disease (GERD).

Ranbaxy Receives USFDA Approval For Cefuroxime Axetil

Ranbaxy LabsIndia’s biggest pharma company, Ranbaxy Laboratories Ltd has announced that it has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Cefuroxime Axetil for Oral Suspension USP, 125 mg/5mL and 250 mg/5mL.

Cefuroxime Axetil Suspension is indicated for the treatment of pediatric patients 3 months to 12 years of age with mild to moderate infections caused by susceptible strains of the designated microorganisms. The drug is used in the treatment of Pharyngitis/Tonsillitis, Acute Bacterial Otitis Media and Impetigo.

Ranbaxy finally receives permission, for its anti-allergic drug

Ranbaxy Labs
India`s biggest pharmaceutical company, Ranbaxy Laboratories Ltd has announced that it has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Cetrizine Hydrochloride Tablets (OTC), in 5 mg and 10 mg doses.

Cetirizine hydrochloride is a generic version of Pfizer's Zyrtec tablets of the same strengths. It is used for temporary relief from running nose, sneezing, itching of the nose or throat, and itchy. The drug is also effective in treatment of watery eyes due to hay fever or other upper respiratory allergies, company stated in a release.

Ranbaxy Labs is good investment at current levels

As per views of Technical Analysts, Ranbaxy Labs is looking very fairly valued at current market price. The stock ended at 433.10 levels on Friday, down by Rs 9.20 or 2.08%.

Ranbaxy has also received US approval for anti-bacterial drug Clarithromycin. The total sales for the drug are estimated at US $100 million.

Ranbaxy has announced on 3rd of October that it is all set to acquire 45% stake in Zenotech for Rs 250 crore. After the deal, Ranbaxy will get a controlling stake of 51% in the Zenotech. The final announcement is expected very soon.

The stock is trading at a P/E of 24.61 at current price. With earnings per share of Rs 17.60 per share, the stock looks a good long term investment.

Ranbaxy gets USFDA nod for Clarithromycin

Ranbaxy Clarithromycin FDA Pharyngitis
New Delhi: Ranbaxy Laboratories has informed that the company has got final FDA approval for its anti-infective agent Clarithromycin. In a press statement, the pharmaceutical major said that US Food and Drug Administration (USFDA) has granted approval for manufacturing and marketing of oral suspension drug Clarithromycin for US markets.

FDA Permits Sale Of Ranbaxy's Drug for Diabetes Cure in the US Market

Ohm LaboratoriesMumbai: Ohm Laboratories, Ranbaxy’s US subsidiary has received the US Food and Drug Administration's (FDA) authorization to sell Metformin Hydrochloride tabs that are exclusively intended for curing diabetes.

The Florida-based Ranbaxy Pharmaceuticals, a wholly-owned subsidiary of Ranbaxy Laboratories also said that it received the permission to sell Metformin Hydrochloride pills in various strengths of 500 mg, 850 mg and 1,000 mg in the US market through Ohm Laboratories.

Ranbaxy Lab Leads The Gainers on BSE Sensex

Ranbaxy Laboratories Ltd.Ranbaxy Laboratories leads the gainers path on the Sensex. In morning trades, the share is quoting at Rs 364.40, which is up Rs 23.35, or 6.85%.

It touched an intraday high of Rs 365.50 and an intraday low of Rs 340 during the day.

Today, the scrip is trading with volumes of 523,094 shares. Yesterday the share ended the day on a dreary note after losing 1.02% or Rs 3.50 at Rs 341.05.

Rising Markets Stimulate Ranbaxy’s Qauterly Income By 118%

Ranbaxy Laboratories Ltd.New Delhi: Actuated by maturation in key emerging markets, India’s leading pharmaceutical company Ranbaxy Laboratories’ net profit for the quarter ended June 30 climbed up 118 percent to Rs 266.2 crore from Rs 122.11 crore in the corresponding period of the last year.

The company’s business in the rising market segments developed 44 per cent in the quarter, adding as much as 54 percent to its worldwide sales.

Syndicate content